Lineage Cell Therapeutics Inc share price logo

Lineage Cell Therapeutics Inc Share Price

NYSE: LCTX

Small Cap

$1.48

-0.01

(-1.01%)

Live

as on

Lineage Cell Therapeutics Inc Stock Performance

as on March 31, 2026 at 1:08 am IST

  • Day's Low

    Day's High

    $1.46
    $1.50
    downward going graph

    1.35%

    Downside

    1.35%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.37
    $2.09
    downward going graph

    75.33%

    Downside

    41.22%

    Upside

    downward going graph

Lineage Cell Therapeutics Inc share price movements today

Previous Close
$1.49
Open
$1.47
Volume
198.1K
Day's Low - High
$1.46 - $1.50
52 Week Low - High
$0.37 - $2.09

Lineage Cell Therapeutics Inc Historical Returns

1 Month Return
-23.59 %
3 Month Return
-6.88 %
1 Year Return
+ 202.91 %
3 Year Return
+ 4.2 %
5 Year Return
-34.07 %

Lineage Cell Therapeutics Inc Stock Fundamentals & Key Indicators

Check Lineage Cell Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$371.1M

EPS (TTM)

-0.06

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-6.85

Industry PE ratio

0

PEG Ratio

10.6379

EBITDA

-21.1M

Revenue (TTM)

14.6M

Profit Margin

0.00%

Return On Equity TTM

-105.30%

Lineage Cell Therapeutics Inc Stock Valuation

Track how Lineage Cell Therapeutics Inc P/E has moved over time to understand its valuation trends.

Lineage Cell Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-32.34x)

June 30, 2021

Industry (0.00x)

March 30, 2026

Today (-6.85x)

March 30, 2026

Highest (-3.30x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -6.85x

Lineage Cell Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Lineage Cell Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Lineage Cell Therapeutics Inc image
Lineage Cell Therapeutics Inc
BUY$371.1M-34.07%-6.850.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$42.1B134.86%136.798.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$110.0B103.33%28.2532.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.5BNA115.055.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.0B56.74%17.7931.41%

Stock Returns calculator for Lineage Cell Therapeutics Inc Stock including INR - Dollar returns

The Lineage Cell Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Lineage Cell Therapeutics Inc investment value today

Current value as on today

₹3,34,705

Returns

₹2,34,705

(+234.7%)

Returns from Lineage Cell Therapeutics Inc Stock

₹2,02,041 (+202.04%)

Dollar Impact

₹32,664 (+32.66%)

Analyst Recommendation on Lineage Cell Therapeutics Inc Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for Lineage Cell Therapeutics Inc. Average target price of $4.5

Lineage Cell Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Lineage Cell Therapeutics Inc.

What analysts predicted

67.11%UPSIDE

Target Price

$4.5

Current Price

$1.48

Analyzed by

12 Analysts

Target

$4.50

Lineage Cell Therapeutics Inc target price $4.5, a slight upside of 67.11% compared to current price of $1.48. According to 12 analysts rating.

Lineage Cell Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Lineage Cell Therapeutics Inc Stock has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-32% versus previous 30 day period

Lineage Cell Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
1
2
1
1
3
2
1
2
3
6
Gross Profit
1
1
1
1
3
2
1
2
3
5
Operating Income
-6
-6
-6
-5
-3
-5
-6
-19
-3
8
EBITDA
-6
-6
-6
-5
-3
-4
-6
-4
-29
19
Interest Expense
-
0
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-7
-4
-6
-5
-3
-3
-4
-30
-29
-4
Income Tax Expense
0
0
0
0
0
0
-
-
-
-5
Net Income
-7
-4
-6
-5
-3
-3
-4
-30
-29
0
Net Profit Margin
-570.63%
-228.69%
-453.05%
-409.09%
-80.29%
-114.12%
-275.57%
-1101.77%
-809.05%
12.88%

Lineage Cell Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
2
1
1
1
0
3
14
8
9
14
Gross Profit
1
1
1
1
0
2
13
8
9
13
Operating Income
-58
-38
-41
-38
-26
-49
-22
-24
-21
-21
EBITDA
-54
-37
-37
-35
-24
-48
-21
-24
-20
-21
Interest Expense
0
0
10
1
5
0
5
-
-
-
Depreciation
-
3
3
3
2
0
0
0
0
0
Income Before Tax
18
-23
-47
-19
-21
-43
-25
-23
-18
-68
Income Tax Expense
-175
-37
0
-7
-1
-4
0
-1
0
-5
Net Income
33
-19
-45
-11
-20
-43
-26
-21
-18
-63
Net Profit Margin
1490.76%
-1114.73%
-3247.88%
-792.22%
-2671.28%
-1104.18%
-178.69%
-240.20%
-195.90%
-436.47%

Lineage Cell Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-4
-6
-5
-3
-3
-4
-30
-29
0
Operating Cash Flow
-6
-5
-5
-5
-6
-4
-5
-3
-4
Investing Cash Flow
9
0
-8
3
2
1
0
0
-15
Financing Cash Flow
0
14
0
0
21
5
0
1
20
Change in Cash
3
8
-13
-1
18
1
-5
-1
0

Lineage Cell Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-23
-46
-11
-20
-43
-26
-21
-18
-63
Operating Cash Flow
-30
-30
-31
-19
-23
1
-28
-23
-18
Investing Cash Flow
-10
11
16
13
9
-46
46
-2
-13
Financing Cash Flow
55
5
0
29
36
1
6
35
26
Change in Cash
14
-13
-14
23
23
-44
24
10
-5

Insights on Lineage Cell Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 1.50M → 6.60M (in $), with an average increase of 38.3% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, LCTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -30.46M → 851.0K (in $), with an average increase of 1800.9% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, LCTX stock has moved up by 202.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 62.6% return, outperforming this stock by 58.4%

About Lineage Cell Therapeutics Inc

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
OrganisationLineage Cell Therapeutics Inc
Headquarters2173 Salk Avenue, Carlsbad, CA, United States, 92008
IndustryHealth Technology
CEOMr. Brian M. Culley M.A., M.B.A.
E-voting on sharesClick here to vote

Key Management of Lineage Cell Therapeutics Inc

Name

Title

Dr. Charlotte Hubbert Ph.D.

Vice President of Corporate Development

Dr. Rami Skaliter M.Sc., Ph.D.

Chief Executive Officer of Cell Cure Neurosciences

Ms. Alexandra Hernandez

Senior Director of Finance & Controller

Dr. Harold D. Waitz

Vice President of Regulatory Affairs & Quality Control

Ms. Jill Ann Howe

CFO & Principal Financial and Accounting Officer

Mr. George A. Samuel III, J.D.

General Counsel & Company Secretary

Ms. Ioana C. Hone

Director of Investor Relations

Ms. Brandi L. Roberts CPA, M.B.A.

Consultant

Mr. Brian M. Culley M.A., M.B.A.

CEO, President & Director

FAQs

What is Lineage Cell Therapeutics Inc share price today?

Lineage Cell Therapeutics Inc share price today is $1.48 as on . Lineage Cell Therapeutics Inc share today touched a day high of $1.5 and a low of $1.46.

What is the 52 week high and 52 week low for Lineage Cell Therapeutics Inc share?

Lineage Cell Therapeutics Inc share touched a 52 week high of $2.09 on and a 52 week low of $0.37 on . Lineage Cell Therapeutics Inc stock price today i.e. is trending at $1.48,which is 29.19% down from its 52 week high and 305.37% up from its 52 week low.

What is Lineage Cell Therapeutics Inc's market capitalisation today?

Lineage Cell Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Lineage Cell Therapeutics Inc Stock (LCTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Lineage Cell Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lineage Cell Therapeutics Inc Shares that will get you 1.0135 shares as per Lineage Cell Therapeutics Inc share price of $1.48 per share as on March 30, 2026 at 7:38 pm IST.

What is the minimum amount required to buy Lineage Cell Therapeutics Inc Stock (LCTX) from India?

Indian investors can start investing in Lineage Cell Therapeutics Inc (LCTX) shares with as little as ₹94.702 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹947.02 in Lineage Cell Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Lineage Cell Therapeutics Inc share’s latest price of $1.48 as on March 30, 2026 at 7:38 pm IST, you will get 6.7568 shares of Lineage Cell Therapeutics Inc. Learn more about fractional shares .

What are the returns that Lineage Cell Therapeutics Inc has given to Indian investors in the last 5 years?

Lineage Cell Therapeutics Inc stock has given -34.07% share price returns and 29.6% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?